Investigating how TREM2 affects immune responses during infections
Role of TREM2 in host defense and immunity during infection
This study is looking at how a special protein called TREM2 helps your immune system fight off infections, and by understanding this better, we hope to find new ways to improve treatments for infections and related health issues.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-11111459 on NIH RePORTER |
What this research studies
This research explores the role of TREM2, a receptor found on immune cells, in how the body defends itself against infections. By using advanced techniques like CRISPR to modify genes, the study aims to understand how TREM2 interacts with other proteins to activate immune responses. The research focuses on how TREM2 helps immune cells recognize and respond to pathogens, which could lead to new insights into treating infections and related diseases. Patients may benefit from a deeper understanding of immune mechanisms that could inform future therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with acute infections or those at risk for infections who may benefit from enhanced immune responses.
Not a fit: Patients with chronic infections or those not experiencing acute immune responses may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for infections and better management of immune-related conditions.
How similar studies have performed: Previous research has shown promising results in understanding immune responses through similar receptor studies, indicating potential for success in this area.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Lodoen, Melissa Bruckner — University of California-Irvine
- Study coordinator: Lodoen, Melissa Bruckner
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.